As Bluebird backpedals from Europe, gene treatment players facial area hurdles

After Bluebird Bio (BLUE) announced strategies this week to end business functions in Europe, the go is increasing contemporary thoughts about the extent to which providing such dear treatment plans is feasible for compact biotechs in 1 of the world’s biggest markets.

In conveying the go, the biotech complained that it has turn out to be a dropping proposition seeking to convince European Union member states to make big upfront payments for therapies that can save wellbeing care techniques much bigger charges later. So as a substitute, the enterprise is shifting its concentrate to the U.S., the place it is a lot more very likely to get reimbursed at the sought after charges.

Unlock this article by subscribing to STAT+ and appreciate your first 30 days no cost!

GET Began

About the author